Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of BBI-4000 (sofpironium bromide) gel in primary axillary hyperhidrosis
jRCT2080223946Phase 3Completed
- Sponsor
- Kaken Pharmaceutical Co., Ltd.
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of sofpironium in essential axillary hyperhidrosis (2 arms), sponsored by Kaken Pharmaceutical Co., Ltd. Started Jun 2018; status: completed.
02
Drugs
sofpironium
03
Conditions
essential axillary hyperhidrosis
Beyond the preview
Go deeper on jRCT2080223946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223946.